Kyowa Hakko Kirin, Novartis deal

Novartis’ Sandoz K.K. granted Kyowa exclusive rights to commercialize a biosimilar of rituximab in Japan. Sandoz will be responsible for gaining marketing authorization and subsequent manufacturing. S...